Skye Bioscience, Inc. (NASDAQ:SKYE) is making waves in the biopharmaceutical industry with its innovative approach to obesity treatment. The company's lead candidate, nimacimab, a CB1 negative ...

Part two of this series sees Ravijyot Saggu explore pharmacological management recommendations from the new joint chronic ...

A small study of Sanofi’s lixisenatide has suggested that the GLP-1 agonist could slow down the progression of Parkinson’s disease, pointing to another potential use for the fast-growing drug ...

The EMA’s safety committee has said that, after a review of available data, it has found no evidence that GLP-1 agonist drugs such as Novo Nordisk’s Ozempic and Eli Lilly’s Trulicity can ...

Scientists have discovered an antibody treatment that may help prevent both muscle loss and bone density loss in people using ...

Chimerix holds the potential to have the first approval of dordaviprone for treating recurrent H3 K27M mutant high-grade ...

Aristotle Atlantic’s Focus Growth Composite posted a total return of 5.05% gross of fees, underperforming the 7.07% total return of the Russell 1000 Growth Index.

This study presents an important discovery regarding the diversity and evolution of gall-forming microbial effectors. Supported by convincing computational structural predictions and analyses, the ...

Furin is identified as the key enzyme responsible for cleaving the apelin precursor. Inhibiting this cleavage could serve as ...

Thetis Pharmaceuticals LLC (“Thetis”), a clinical-stage company developing TP-317, a first-in-class, small molecule drug ...

When is the Elden Ring Nightreign beta? The Lands Between beckons us once more for a standalone expansion that introduces a roguelike loop into FromSoftware’s formula. Playtests are the perfect ...